ViGeneron, a gene therapy company, and WuXi Advanced Therapies, a contract, testing, development, and manufacturing organization (CTDMO), entered into a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program.

ViGeneron’s lead product, VG901, targets a disease gene for Retinitis pigmentosa (RP), for which there is currently no approved treatment option. The company said VG901 is developed from its proprietary next generation vgAAV vector platform that allows transduction of retinal cells and intravitreally, a less invasive treatment administration.

WuXi expects to accelerate the development of VG901 by manufacturing, testing, and making available the clinical trial grade treatment while leveraging its AAV suspension and plasmid DNA platforms.

“We are excited to partner with WuXi Advanced Therapies to access their integrated platforms, expertise and cGMP manufacturing capabilities to advance our ongoing development,” said Caroline Man Xu, PhD, co-founder and CEO of ViGeneron. “We are well on track to kick off the manufacturing of our lead product, VG901, by close of 2020 to bring our innovative gene therapy into the clinic and to patients in need.”